Skip to main content

Table 1 Demographic, disease status and medication information among neonatal patients using digoxin on modeling dataset or validation dataset

From: Predicting the serum digoxin concentrations of infants in the neonatal intensive care unit through an artificial neural network

 In modeling datasetIn validation datasetp-value a
 Number of observations (male/female)139 (81/58)29 (13/16) 
 Number of patients (male/female)71 (40/31)19 (7/12) 
Demographic
 Gender (Male/Female)81/5813/160.185
 Postnatal age (week)36.35 ± 8.08b, (34)c38.41 ± 5.14b, (37)c0.190
 Total body weight (kg)1.73 ± 0.90b, (1.44)c1.88 ± 0.72b, (1.76)c0.407
Diseases
 CHF54 (38.8)11 (37.9)0.926
 DCM9 (6.5)4 (13.8)0.243
 PH11 (7.9)7 (24.1)0.010
 VSD16 (11.5)9 (28.1)0.072
Medications
 Ibuprofen61 (38/23)11 (3/8)0.556
 Captopril6 (6/0)4 (4/0)0.072
 Furosemide24 (20/4)5 (4/1)0.997
Digoxin information
 Digoxin dose (mcg∙kg−1∙d−1)5.90 ± 1.93, (5.19)5.66 ± 1.81, (5.17)0.542
 Drug concentrations (ng/mL)1.25 ± 0.38, (1.2)1.14 ± 0.24, (1.06)0.138
  1. a. Nonparametric test by t-test for continuous data and Pearson’s Chi-Square test for categorized data; b. Values are expressed as mean ± SD; c. Median Value (IQR); CHF Congestive Heart Failure; DCM dilated cardiomyopathy; PH pulmonary hypertension; VSD Ventricular Septal Defect